Allergic Rhinitis clinical trials

Explore recruiting allergic rhinitis clinical trials.

Recruiting allergic rhinitis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Allergic Rhinitis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of PQ Birch in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by birch pollen exposure

Austria, Germany, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A prospective, randomized, double-blind placebo-controlled multicentre study with mannan-conjugated birch pollen allergoids administered subcutaneously to adolescent and adult patients with birch pollen-induced allergic rhinitis or rhinoconjunctivitis.

Germany, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy (Beltavac®) with Polymerized Allergenic Extract of a Mixture of Dermatophagoides and Blomia tropicalis in Patients with Allergic Rhinitis/rhinoconjunctivitis.

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

EVALUATION OF THE EFFICACY AND SAFETY OF SUBCUTANEOUS IMMUNOTHERAPY (BELTAVAC®) WITH POLYMERIZED ALLERGENIC EXTRACT OF HOUSE DUST MITE MIXTURE IN PATIENTS WITH ALLERGIC RHINITIS/RHINOCONJUNCTIVITIS

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A study to investigate pharmacokinetics and safety of rupatadine (10 mg) and its active metabolites in participants with renal impairment compared to matched control participants with normal renal function.

Spain, Portugal

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/ LY3650150 in Adult Participants With Perennial Allergic Rhinitis

Poland, Germany, Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

Allergic Rhinitis trials by city

Allergic Rhinitis in Toronto Allergic Rhinitis in Vancouver Allergic Rhinitis in Montreal Allergic Rhinitis in Calgary Allergic Rhinitis in Edmonton Allergic Rhinitis in Ottawa Allergic Rhinitis in Winnipeg Allergic Rhinitis in Quebec City Allergic Rhinitis in Hamilton Allergic Rhinitis in Kitchener Allergic Rhinitis in London Allergic Rhinitis in Halifax Allergic Rhinitis in New York Allergic Rhinitis in Los Angeles Allergic Rhinitis in Chicago Allergic Rhinitis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease